导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -15.39% | 4138/4773 |
| 近一周 | -3.30% | 3919/5458 |
| 近一月 | -2.10% | 1379/5421 |
| 近一季 | 1.00% | 767/5205 |
| 近半年 | -14.23% | 3950/4920 |
| 近一年 | -23.42% | 4046/4361 |
| 近两年 | -1.16% | 2909/2954 |
| 近三年 | -28.45% | 2207/2253 |
| 成立以来 | -2.01% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.77% 3940/4961 |
-16.38% 4732/5312 |
- - |
- - |
| 2025 | -2.85% 3344/4813 |
-0.51% 2278/3635 |
-2.18% 3322/4076 |
6.04% 3555/4524 |
-5.86% 3633/4813 |
| 2024 | -5.17% 2263/3463 |
0.87% 929/2808 |
-9.22% 2334/3014 |
13.60% 2150/3129 |
-8.84% 2884/3463 |
| 2023 | -15.88% 1662/2656 |
2.36% 1364/2280 |
-12.09% 2173/2385 |
-0.88% 460/2515 |
-5.69% 1465/2655 |
| 2022 | -11.98% 266/2207 |
-15.83% 1076/1919 |
14.36% 199/2016 |
-8.78% 226/2113 |
0.24% 1520/2208 |
| 2021 | -4.61% 954/1822 |
-5.62% 941/1255 |
4.01% 935/1330 |
-9.34% 1174/1466 |
7.19% 193/1822 |
| 2020 | - - |
- - |
- - |
15.10% 235/1164 |
20.30% 63/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 嘉实中证主要消费ETF发起联接C VS. 长安沪深300非周期A(740101) |